Santhera Completes Capital Increase for Financing Arrangements

Pratteln, Switzerland, June 16, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 870,000 reserve shares. The number of shares recorded in the commercial register has been increased to 13,185,063 shares.

On June 16, 2020, 870,000 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for purposes of its financing arrangements with IRIS and Highbridge Capital. The new shares will be listed as per June 17, 2020.

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age. A marketing authorization application for Puldysa® (idebenone) is currently under review by the European Medicines Agency. Santhera has an option to license vamorolone, a first-in-class anti-inflammatory drug candidate with novel mode of action, currently investigated in a pivotal study in patients with DMD to replace standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com. 

Raxone^® and Puldysa^® are trademarks of Santhera Pharmaceuticals.